--- title: "Adlai Nortye (NASDAQ:ANL) Reaches New 52-Week High - Should You Buy?" type: "News" locale: "en" url: "https://longbridge.com/en/news/282726221.md" description: "Adlai Nortye (NASDAQ:ANL) reached a new 52-week high of $14.30, closing at $13.8150 with a trading volume of 195,199 shares. Analysts have mixed opinions: Weiss Ratings maintains a 'sell' rating, while Leerink Partners set an 'outperform' rating with a $23 target. HC Wainwright upgraded it to 'buy' with a $16 target. The stock has a consensus rating of 'hold' and an average target price of $19.50. Adlai Nortye specializes in fine chemicals, particularly amino acids, serving various markets including animal feed and pharmaceuticals." datetime: "2026-04-14T17:00:48.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282726221.md) - [en](https://longbridge.com/en/news/282726221.md) - [zh-HK](https://longbridge.com/zh-HK/news/282726221.md) --- # Adlai Nortye (NASDAQ:ANL) Reaches New 52-Week High - Should You Buy? Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $14.30 and last traded at $13.8150, with a volume of 195199 shares changing hands. The stock had previously closed at $12.06. ## Analyst Upgrades and Downgrades Several research firms have recently weighed in on ANL. Weiss Ratings reiterated a "sell (e+)" rating on shares of Adlai Nortye in a research note on Wednesday, January 21st. Leerink Partners began coverage on shares of Adlai Nortye in a report on Friday, March 20th. They set an "outperform" rating and a $23.00 target price on the stock. Wall Street Zen upgraded Adlai Nortye to a "hold" rating in a research report on Saturday, March 7th. Finally, HC Wainwright upgraded Adlai Nortye from a "neutral" rating to a "buy" rating and set a $16.00 price target for the company in a research report on Friday, February 13th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $19.50. **Read Our Latest Research Report on Adlai Nortye** ## Adlai Nortye Stock Performance The stock's fifty day moving average is $8.91 and its two-hundred day moving average is $4.34. ## Adlai Nortye Company Profile (Get Free Report) Adlai Nortye Inc NASDAQ: ANL is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives. Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes. The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control. ## Recommended Stories - Five stocks we like better than Adlai Nortye _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Adlai Nortye Right Now? Before you consider Adlai Nortye, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adlai Nortye wasn't on the list. While Adlai Nortye currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [ANL.US](https://longbridge.com/en/quote/ANL.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) ## Related News & Research - [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md) - [AbbVie Inc. $ABBV Shares Purchased by RiverFront Investment Group LLC](https://longbridge.com/en/news/286750290.md) - [Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention](https://longbridge.com/en/news/286884841.md) - [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md) - [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md)